For example, germline mutations of the ALK receptor tyrosine kinase (ALK) gene are involved in the etiology of a subset of neuroblastomas (Mosse et al., 2008) and somatic ALK gain-of-function mutations, gene amplifications, and gene fusions are oncogenic drivers and therapeutic targets for neuroblastoma and anaplastic large cell lymphoma (Mosse et al., 2017). This evidence concerns the gene NTRK1 and neuroblastoma.